Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)
Phase of Trial: Phase III
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Prasterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- Sponsors Endoceutics
- 06 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 06 Feb 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2018.
- 31 Oct 2017 Status changed from not yet recruiting to recruiting.